The intersection of metabolic interventions and hormone regulation reveals new complexity in cancer treatment approaches. While intermittent fasting has gained attention for potential anti-cancer properties, emerging evidence suggests the stress hormone response during fasting periods may create unexpected interactions with breast cancer biology. Glucocorticoids, primarily cortisol, surge during extended fasting as the body mobilizes energy reserves. These steroid hormones can influence immune function, cell proliferation, and inflammatory pathways—all critical factors in cancer progression and treatment response. The relationship appears particularly relevant for hormone-sensitive breast cancers, where cortisol may interact with estrogen signaling pathways. This hormonal interplay during fasting states could potentially alter how cancer cells respond to therapeutic interventions, though the directional effects remain under investigation. The findings add nuance to the growing body of research on time-restricted eating and cancer outcomes. While some studies have suggested metabolic benefits from fasting protocols, the glucocorticoid response introduces a variable that may differ significantly between individuals based on stress resilience, baseline cortisol patterns, and cancer subtype. For clinicians considering fasting-based interventions alongside conventional breast cancer treatment, this hormonal dimension represents an important consideration that may require personalized monitoring. The research underscores how seemingly beneficial lifestyle interventions can have complex physiological consequences that warrant careful evaluation in cancer care contexts.